Welcome to our dedicated page for Mink Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on Mink Therapeutics stock.
MiNK Therapeutics, Inc. (INKT) is a clinical-stage biopharmaceutical company pioneering allogeneic iNKT cell therapies for cancer and immune-mediated diseases. This page provides investors and industry observers with timely updates on material developments, including clinical trial progress, regulatory milestones, and strategic partnerships.
Access verified press releases and news articles covering MiNK Therapeutics' innovative pipeline, manufacturing advancements, and collaborative research initiatives. Content spans earnings announcements, trial data disclosures, executive leadership updates, and scientific presentations relevant to the company’s position in the immunotherapy sector.
Bookmark this page for streamlined tracking of INKT’s progress in developing off-the-shelf cellular therapies. Check regularly for authoritative updates that inform analysis of the company’s scientific and commercial trajectory.
MiNK Therapeutics (NASDAQ: INKT) has appointed Dr. Robert Kadlec to its Board of Directors. Dr. Kadlec, former U.S. Assistant Secretary for Preparedness and Response at HHS, brings extensive expertise in biodefense and pandemic preparedness. He previously co-conceived Operation Warp Speed and directed pandemic response for HHS during COVID-19. His appointment aims to accelerate MiNK's development of allogeneic off-the-shelf invariant natural killer T (iNKT) cell therapies for infectious diseases, including pathogen-agnostic acute respiratory distress syndrome (ARDS) and emerging threats.
MiNK Therapeutics (NASDAQ: INKT) announced two poster presentations at the Society for Immunotherapy of Cancer's 29th Annual Meeting in Houston, Texas, from November 6-10, 2024. The presentations will showcase new preclinical data from MiNK's iNKT cell programs, agenT-797 and PRAME-TCR.
The first presentation, titled 'AgenT-797 cell therapy can be combined with next-generation immune checkpoint inhibitors (ICI) and / or bi-specific engagers to improve anticancer response,' is scheduled for Friday, November 8th (Abstract Number: 753).
The second presentation, 'PRAME-TCR iNKT cell therapy: Opportunity for best-in-class off-the-shelf solid tumor therapy targeting PRAME,' will take place on Saturday, November 9th (Abstract Number: 374).
MiNK Therapeutics is a clinical-stage biopharmaceutical company focusing on the development of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases.
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focusing on allogeneic iNKT cell therapies, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024. Dr. Jennifer Buell, CEO of MiNK, will engage in a fireside chat on Monday, September 9th at 7:00 a.m. ET.
Investors can register for the event online, and a replay will be available on MiNK's website afterward. This conference provides an opportunity for MiNK to showcase its progress in developing innovative therapies for cancer and other immune-mediated diseases to a global investment audience.
MiNK Therapeutics (NASDAQ: INKT) reported Q2 2024 results and provided a business update. Key highlights include:
- Expanded access to AgenT-797 in severe ARDS shows clinical efficacy
- Phase 2 study in 2L gastric cancer advancing with early data expected soon
- Phase 1 study in GvHD on track for activation in Q2 2024
- Successful PIPE financing raised $5.8 million at 25% premium
- Cash runway extended into 2025
- Q2 net loss of $2.7 million ($0.07 per share), down from $6.2 million ($0.18 per share) in Q2 2023
- Cash balance of $9.3 million as of June 30, 2024
MiNK is advancing its iNKT cell therapy programs, with promising results in ARDS and plans to fast-track IND filing for MiNK-215 CAR-iNKT therapy to early 2025.
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies, has announced its plans to release second quarter 2024 financial results on August 13, 2024, before the market opens. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results and provide a corporate update. Interested parties can access the call via provided dial-in numbers or join the live webcast through the company's investor relations website.
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases, has regained compliance with the Nasdaq Capital Market's market value of listed securities (MVLS) requirement. The company received confirmation from NASDAQ on July 23, 2024, that it has satisfied the MVLS requirement as outlined in Nasdaq Listing Rule 5550(b)(2). This development ensures MiNK Therapeutics' continued listing on the NASDAQ Capital Market, and the matter is now considered closed.
MiNK Therapeutics (NASDAQ: INKT) will hold its Annual Shareholders Meeting virtually on June 12, 2024, starting at 9:30 a.m. ET. Shareholders can register from 9:15 a.m. ET by visiting www.virtualshareholdermeeting.com/INKT2024 and using their 16-digit control number from proxy materials. Guests can access the meeting in listen-only mode without a control number. A live webcast and replay will be available on the company's website.
MiNK Therapeutics has unveiled clinical data on their allogeneic invariant natural killer T (iNKT) cell therapy, agenT-797, in a severe ARDS case at the ATS Annual Meeting. The subject, a 26-year-old post-renal transplant immunocompromised individual who developed severe hypoxemic respiratory failure due to COVID-19, was treated with a single dose of agenT-797. Significant clinical improvements included reduced inflammatory cytokines and successful extubation by day 37. The patient was discharged by day 60 and resumed normal activities within six months. These findings align with Phase 1 trial data, supporting the potential of agenT-797 in treating severe respiratory conditions in immune-compromised patients.
MiNK Therapeutics (NASDAQ: INKT) reported its Q1 2024 results, highlighting significant progress in its invariant natural killer T (iNKT) cell therapy programs. Key developments include a $5.8 million private placement financing at a 25% premium, which will expedite the clinical entry of MiNK-215 for solid tumors. Clinical trials for agenT-797 in gastroesophageal cancers are ongoing, with initial results expected later in 2024. Preclinical data showcased MiNK-215's potential in treating MSS colorectal cancer liver metastases. Financially, MiNK ended the quarter with $5.8 million in cash, reduced net losses to $3.8 million (down from $5.7 million in Q1 2023), and decreased operating expenses.
MiNK Therapeutics, Inc. announced a $5.8 million private placement financing to advance the clinical trials of MiNK-215, their leading allogeneic CAR-iNKT cell therapy targeting fibroblast activation protein in solid tumors. The financing includes a 25% premium, selling 4,640,000 shares of common stock at $1.25 per share. The funding will help accelerate the clinical development of MiNK-215, planned to enter the clinic in early 2025. Additionally, Katie Chudnovsky has been appointed as a Board Observer, bringing extensive experience in the medical research field.
